Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review

被引:9
|
作者
Lopez-Lopez, Jose P. [1 ,2 ]
Gonzalez, Ana Maria [1 ]
Lanza, Paola [1 ]
Lopez-Jaramillo, Patricio [1 ,3 ]
机构
[1] Univ Santander UDES, MASIRA Res Inst, Bucaramanga, Santander, Colombia
[2] Pontificia Univ Javeriana, Hosp Univ San Ignacio, Dept Internal Med, Cardiol Unit, Bogota, Colombia
[3] Univ Santander UDES, MASIRA Res Inst, Fac Ciencias Salud, Bloque G,Piso 6, Bucaramanga, Santander, Colombia
关键词
polypill; cardiovascular disease; hypertension; dyslipidemia; major cardiovascular events; DOSE COMBINATION TREATMENT; HIGH-RISK; BLOOD-PRESSURE; STRATEGY; TRIAL; DRUGS;
D O I
10.2147/VHRM.S421024
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background: Higher medication adherence reduces the risk of new cardiovascular events. However, there are individual and health system barriers that lead to lower adherence. The polypill has demonstrated benefits in cardiovascular morbidity and mortality mainly driven by an increase in adherence. We aim to evaluate the impact of the polypill on adherence to cardiovascular medication, its efficacy and safety in cardiovascular disease (CVD) prevention. Methods: A systematic review following PRISMA guidelines was conducted. Databases were searched from January 2003 to December 2022. We included randomized, pragmatic, or real-world clinical trials and observational studies. The primary outcome was medication adherence, secondary outcomes were efficacy in cardiovascular disease in primary and secondary prevention and safety. Results: From the 490 publications screened, 13 met the inclusion criteria and were incorporated into a comparative table Of those included, 70% were randomized controlled trials (RCTs) and 53.8% focused on secondary prevention. Most of the studies received a high and moderate quality rating. Self-report, pill counting and, the Morisky scale were the most frequent methods to evaluate adherence (84.6%). Compared with standard medication, the polypill improved overall medication adherence by 13%, with percen-tages ranging from 7.6% to 34.9%. Moreover, a potential benefit was also observed in reducing Major Adverse Cardiovascular Events (MACE), particularly in secondary prevention studies, with hazard ratios ranged between 0.43 to 0.76. Compared to standard care, the profile of side effects was similar. Conclusion: The polypill is an effective, safe, and practical strategy to improve adherence in people at risk of CVD. Although there is a demonstrated benefit in reducing MACE, predominantly in secondary prevention, there are still gaps in its efficacy in primary prevention and reducing total mortality. Therefore, the importance of obtaining long-term results of the polypill effect and how this strategy can be implemented in real practice.
引用
收藏
页码:605 / 615
页数:11
相关论文
共 50 条
  • [41] Multifactorial Prevention of Cardiovascular Disease in Patients with Hypertension: the Cardiovascular Polypill
    M. Lafeber
    W. Spiering
    F. L. J. Visseren
    D. E. Grobbee
    Current Hypertension Reports, 2016, 18
  • [42] A Polypill Strategy to Improve Global Secondary Cardiovascular Prevention From Concept to Reality
    Castellano, Jose M.
    Sanz, Gines
    Ortiz, Antonio Fernandez
    Garrido, Ester
    Bansilal, Sameer
    Fuster, Valentin
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (06) : 613 - 621
  • [43] The role of mHealth for improving medication adherence in patients with cardiovascular disease: a systematic review
    Gandapur, Yousuf
    Kianoush, Sina
    Kelli, Heval M.
    Misra, Satish
    Urrea, Bruno
    Blaha, Michael J.
    Graham, Garth
    Marvel, Francoise A.
    Martin, Seth S.
    EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES, 2016, 2 (04) : 237 - 244
  • [44] The impact of dietary patterns on gut microbiota for the primary and secondary prevention of cardiovascular disease: a systematic review
    Yu, Junwen
    Wu, Yue
    Zhu, Zheng
    Lu, Hongzhou
    NUTRITION JOURNAL, 2025, 24 (01)
  • [45] Polypill use for the prevention of cardiovascular disease: A position paper
    Araujo, Francisco
    Caldeira, Daniel
    Aguiar, Carlos
    Antunes, Jose Pedro
    Cardim, Nuno
    Cunha, Vitoria
    Fonseca, Luisa
    Moura, Jose P.
    Paixao-Dias, Vitor M.
    Ribeiro, Hugo
    Cruz, Vitor Tedim
    Gavina, Cristina
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2023, 42 (10) : 861 - 872
  • [46] Polypills for Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis
    Kandil, Omneya A.
    Motawea, Karam R.
    Aboelenein, Merna M.
    Shah, Jaffer
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [47] The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population
    van Gils, Paul F.
    Over, Eelco A. B.
    Hamberg-van Reenen, Heleen H.
    de Wit, G. Ardine
    van den Berg, Matthijs
    Schuit, Albertine J.
    Engelfriet, Peter M.
    BMJ OPEN, 2011, 1 (02):
  • [48] Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK
    Becerra, Virginia
    Gracia, Alfredo
    Desai, Kamal
    Abogunrin, Seye
    Brand, Sarah
    Chapman, Ruth
    Garcia Alonso, Fernando
    Fuster, Valentin
    Sanz, Gines
    BMJ OPEN, 2015, 5 (05):
  • [49] Quality indicators for the primary prevention of cardiovascular disease in primary care: A systematic review
    Bam, Kiran
    Olaiya, Muideen T.
    Cadilhac, Dominique A.
    Redfern, Julie
    Nelson, Mark R.
    Sanders, Lauren M.
    Sundararajan, Vijaya
    Andrew, Nadine E.
    Murphy, Lisa
    Kilkenny, Monique F.
    PLOS ONE, 2024, 19 (12):
  • [50] Cardiovascular Disease in Women Primary and Secondary Cardiovascular Disease Prevention
    Sanghavi, Monika
    Gulati, Martha
    OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA, 2016, 43 (02) : 265 - +